Литература

1. Bangemann N, Burslein H, Harvey V. cl at. Trastuzumab. A Review ofils Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2. Dmgs 2002;62:209-43.  2. Jahanzeb M, Mortimer JE, Yunus F, ct al. Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Mctastalic Breast Cancer. Oncologist 2002:7:410-7.  3. Slamon DJ. 2001 Update on Taxoter/Platinum/ Hcrceptin combinations. Satellite meeting of the 24th San Antonio Breast Cancer Symposium. San Antonio, TX, USA. .  4. Bangcmann N, Kuhle A, Ebert A, et a]. Capecitabine combined with Trastuzumab in the therapy of intensively pretreatcd HER2-overex-pressing metastatic breast cancer [abstract]. Ann Oncol2000;ll(suppl.4):143.  5. Miller KD, Sisk J, Ansari R, et al. Gcmcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology 2001;15(suppl. 3):38-40.  6. Harries M, Smith 1. The development and clinical use of trastuzumab (Herceptin). Endocrine-Related Cancer 2002,9:75-85.  7. Baselga J. Combined anti - EOF receptor and anti - HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing. Ann Oncol 2002:13:8-9.  8. Crone SA, Zhao YY, Fan L, el al. ErbB2 is essential in the prevention of dilated cardiomyopathy J Natur Med 2002:8(5).  9. Safran H, Ramanathan R. Schwartz J, et al. Herceptin and gemcitabine for metastatic pancre  atic cancers that overexpress HER-2/neu [abstract). ECCO 2001.  10. Heinmoeller P, Gross C, Schmidtgen C, et al. HER2 status in non-small cell lung cancer: results from the patient screening for enrolment to a phase 2 study of herceptin [abstract]. Eur J Cancer 2001;37(suppl.6).  11. Tran HT, Herbst RS, Glisson BS, et al. Herceptin in combination with Cisplatin and Gcmcitabine in patients with HER2 Overexpressing, untreated, advanced. Non-small-cell Lung Cancer: Final report of a phase 11 trial [abstract]. Proc ASCO 2002.  12. Hwang JJ, Sinicrope F, Safran H, et al. A phase II Trial of Irinotccan and Trastuzumab in patients Overexpressing HER-2/neu in metastatic colorec-tal cancer [abstract]. Proc ASCO 2001.  13. Hussain M, Smith DC, AI-Sukhum S, et al. Preliminary results of HER-2/neu screening and treatment with Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in patients with advanced urothelial cancer [abstract]. Proc ASCO 2002.  14. Izumi Y, Xu L, di Tomaso E, et al. Tumor biology:  Herceptin acts as an anti-angiogenic cocktail. Nature 2002;416:279-80.  15. Jacobs TW, Gown AM, Yaziji H,elal. Comparison of Fluorescence in situ hybridization and immuno-histochcmistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999;17:1974-82.  16. Graziano C. HER-2 breast assay, linked to Herceptin, wins FDA's okay. CAP Tuday 1998;12:13-16.  17. Jacobs TW, Giown AM, Yaziji H, el al. Spcciticity of HercepTcst in determining HER-2/neu status of breast cancers using United States food and Drug administration-approved scoring system. J Clin Oncol 1999; 17:1983-7.  18. Hcrceptin (Trastuzumab) full prescribing information. Gcnentech, Inc. South San Francisco, CA, USA, September 1998.  19. Bose S, Mohammed M, Shintaku P, Rao PN. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neupolysomy. Breast 2002:7:337-44.  20. Yamauchi H, Steams V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;! 9:2334-56.  21. Carbonell Castcllon X, et al. Efficacy and safety of 3-wcckly Herceptin monotherapy in women with HER-positive metastatic breast cancer [abstract]. Proc ASCO 2002; 19.  22. Pegram M, Hsu S, Lewis G.etal. Inhibitory effects of combinations of HER-2/neu antibody and chemothcrapeiitic agents used for treatment of human breast cancers. Oncogene 1999:18:2241-51.  23. Mann M, et al. Targeting cyclooxygenase 2 and HER2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001; 120:1713-9.  24. Normanno N, et al. Cooperative inhibitory effect of ZD 1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cell growth. Ann Oncol 2002; 13:65-72